Vanda Pharmaceuticals

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vanda Pharmaceuticals reports mixed Q4 results amid legal challenges and opportunities

Vanda Pharmaceuticals faces financial challenges with declining revenues and HETLIOZ sales, offset by increased cash reserves and positive clinical trial outcomes.
Legal battles and uncertainties add complexity to the company's financial outlook, requiring strategic planning and risk management.
Despite hurdles, opportunities for growth exist through new drug applications, market expansion, and potential partnerships to drive future success.

Vanda Pharmaceuticals reports resilient Q1 performance amidst generic challenges

Vanda Pharmaceuticals delivered a strong performance in Q1 2023, navigating challenges from generic competition while focusing on growth opportunities.
The company's financial results and strategic initiatives position it well for future expansion and innovation in the pharmaceutical industry.
Despite uncertainties surrounding litigation and generic competition, Vanda remains resilient and committed to driving long-term value for stakeholders.

Vanda Pharmaceuticals navigates revenue decline, eyes regulatory approvals for growth

Vanda Pharmaceuticals faced revenue challenges due to generic competition impacting HETLIOZ sales, leading to a revenue decline.
Despite legal uncertainties and revenue setbacks, the company showcased strength in pipeline progress and operational cost management.
Management's confidence in regulatory outcomes and strategic flexibility positions Vanda for potential growth opportunities.

Vanda Pharmaceuticals reports revenue decline but maintains positive net income

Vanda Pharmaceuticals faces revenue challenges with declining total revenues and net product sales in 2023.
Despite this, the company maintains positive net income and focuses on upcoming FDA decisions for growth.
Strong leadership, operational efficiency, and a diversified product portfolio are key strengths for Vanda.
Exploring growth opportunities through FDA decisions, market expansion, and strategic initiatives is crucial for future success.

Vanda Pharmaceuticals reports revenue decline, pursues new treatments amid challenges

Vanda Pharmaceuticals faced revenue declines and net losses in Q4 2023, driven by challenges in product sales and market conditions.
Despite these setbacks, the company is strategically expanding its product portfolio and pursuing new treatments to drive future growth.
Navigating legal battles, generic competition, and market uncertainties will be key focus areas for Vanda in the coming year.

Vanda Pharmaceuticals navigates revenue challenges, eyes growth through strategic initiatives

Vanda Pharmaceuticals faced revenue challenges due to generic competition but remains focused on driving growth through commercial strategies.
The company's psychiatry portfolio expansion and ongoing clinical programs position it well for future market opportunities.
Addressing shareholder activism and evaluating takeover proposals while maintaining operational focus are key challenges ahead.
Engaging with the FDA for product approvals and planning strategic marketing initiatives offer avenues for revenue growth.

Vanda Pharmaceuticals reports revenue growth and strategic expansion plans

Vanda Pharmaceuticals is navigating a mixed financial performance with revenue growth but a net loss in Q2 2024. The company's focus on expanding its commercial organization and advancing clinical development indicates a strategic approach to drive future growth amidst challenges from generic competition.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vanda Pharmaceuticals (NASDAQ: VNDA) shares are trading lower on Tuesday, after Citigroup downgraded the stock from Buy to Neutral and announced a price target of $14 per share.

Why Vanda's Stock Is Trading Lower Today

WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda's motion to dismiss a False Claims Act lawsuit filed against the company. On May 19, 2020, Judge Amit P. Mehta...

Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit

WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharmaceuticals, proposing an approach to Clinical Trial Data Sharing in order to facilitate discovery...

Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir

No matter how much courage an investor has, investing in cheap stocks that have pending whistleblower lawsuits against them just isn't a good idea.

1 Pharma Stock to Avoid at All Costs

Third-quarter results from a COVID-19 trial could send this stock soaring.

This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19

Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2020 Results - Earnings Call Transcript

Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and 0.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Meets Q1 Earnings Estimates

Vanda Pharmaceuticals: Undervalued Despite Its COVID-19 Treatment Potential

Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.

Vanda Begins Enrollment in Study for Severe Coronavirus Infection

Vanda Pharmaceuticals' (VNDA) CEO Mihales Polymeropoulos on Q4 2019 Results - Earnings Call Transcript

First Horizon National

Janus Henderson Group

PG&E

Principal Financial Group

THL Credit

A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.

7 Stocks With Low Price-to-Sales Ratio for a Solid Portfolio

Vanda Loses Against The FDA, And Other News: The Good, Bad, And Ugly Of Biopharma

FormFactor

iRobot

On the tailwind of a growing U.S. economy, in which gross domestic product is projected to have hit a 2% annualized gain in the final quarter of 2019, the Russell 2000 Index rose 25.8% to $1,657.64 per share over the past year through Friday, Jan. 10.

3 Small Caps to Consider for Growth

Vanda: Significantly Underappreciated

CNX Resources

Cooper-Standard Holdings

Concho Resources

Green Dot

These five stocks should benefit from the “January bounce” that often buoys up the previous year’s losers.

5 Stocks With January Bounce-Back Potential

Energy stocks, and to a lesser extent bank stocks, have been the market’s whipping boys in 2019.

These Stocks Could Bounce High in January and Beyond

Vanda Pharmaceuticals' (VNDA) CEO Mihales Polymeropoulos on Q3 2019 Results - Earnings Call Transcript

Vanda Pharmaceuticals (VNDA) receives a CRL from the FDA for the sNDA of Hetlioz (tasimelteon) to treat Jet Lag Disorder.

Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) received a negative FDA verdict on its drug Hetlioz, the company said Monday.

FDA Issues Complete Response For Vanda's Hetlioz In Jet Lag Disorder

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares dropped early to begin the week after the firm announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA).

Why the FDA Is a Little Slow on This Jet Lag Study

Small-cap biopharma Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has withstood the market-wide sell-off witnessed in early August, thanks to the second-quarter report the company issued July 31.

Biotech Stock On The Radar: Is Vanda A Buy Ahead Of Its PDUFA Date?

Vanda (VNDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Vanda (VNDA) Might be Well Poised for a Surge

The stock popped after the company reported a solid quarter of operations, but serious red flags remain.

Vanda Pharmaceuticals Returns to Profitability in Q2

Sales of Hetlioz and Fanapt are exceeding expectations.

Here's Why Vanda Pharmaceuticals Stock Soared on Thursday

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2019 Results - Earnings Call Transcript

News for Vanda Pharmaceuticals Stock (VNDA)